Monthly information on share capital and company voting rights
June 13, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
May 15, 2023 09:15 ET
|
Gracell Biotechnologies Inc.
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 15, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated...
Yasheng Group Notifies FINRA of Plan to Pay Preferred Dividend to Common Shareholders
March 01, 2023 06:00 ET
|
Yasheng Group
San Jose, CA, March 01, 2023 (GLOBE NEWSWIRE) -- Yasheng Group Notifies FINRA of Plan to Pay Preferred Dividend to Common Shareholders; Begins Raising Capital for our Subsidiary, Jove Pharmaceutics...
Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development
February 24, 2023 03:30 ET
|
Yasheng Group
San Jose, California, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Yasheng's AI-Powered Cancer Therapy Patent Revolutionizes Immunotherapy Development SAN JOSE, CA--(February 24, 2023) - Yasheng Group, (OTC:...
The CAR-T cell therapy market is projected to grow at an annualized rate of 23%, claims Roots Analysis
February 15, 2023 10:00 ET
|
Roots Analysis
London, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Global CAR-T Cell Therapy Market (4th Edition), 2022-2035 ” report to its list of offerings. CAR-T cell...
Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01
February 09, 2023 01:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023 18:43 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023 16:36 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
December 11, 2022 10:00 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster...
Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
November 10, 2022 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...